Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA

Morphology was once the only means of classifying blood cancers especially CLL; flow cytometry, cytogenetics and immunohistochemistry all followed. With a revolution in understanding, there is now a growing list of molecular tests that provide even more precise diagnostic and prognostic tools in diagnosis and treatment decisions. In this episode, Dr. Ken Miller speaks with Dr. Jennifer Brown from the Dana-Farber Cancer Institute about cancer genomics, its current applications in diagnosis, prognosis, treatment decisions, risk of recurrence, and the future of genomics testing in hematologic malignancies. Tune in to this informative conversation today!

Director, CLL Center

Dana-Farber Cancer Institute

Professor of Medicine, Harvard Medical School

Institute Physician

Dana-Farber Cancer Institute

Boston, MA